Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
Floris H.B.M. Schreuder,Koen M. van Nieuwenhuizen,Jeannette Hofmeijer,Sarah E. Vermeer,Henk Kerkhoff,Elles Zock,Gert-Jan Luijckx,Gert P Messchendorp,Julia H. van Tuijl,H. Paul Bienfait,Suzanne J Booij,Ido R. van den Wijngaard,Michel J M Remmers,Antonia H C M L Schreuder,Diederik W.J. Dippel,Julie Staals,P. J. A. M. Brouwers,Marieke J.H. Wermer,Jonathan M. Coutinho,Vincent I. H. Kwa,Isabelle C. Van Gelder,Roger E. G. Schutgens,Berber Zweedijk,Ale Algra,Jan Willem van Dalen,L. Jaap Kappelle,Gabriel J.E. Rinkel,H. Bart van der Worp,Catharina J.M. Klijn,Apache-Af Trial Investigators +29 more
TL;DR: The APACHE-AF trial as discussed by the authors was a prospective, randomised, open-label, phase 2 trial with masked endpoint assessment, done at 16 hospitals in the Netherlands and aimed to estimate the rates of non-fatal stroke or vascular death in such patients when treated with apixaban compared with when anticoagulation was avoided, to inform the design of a larger trial.
Journal ArticleDOI
Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor.
TL;DR: This review highlights the increased risk of cardiovascular disease and the dismal prognosis after acute coronary events when diabetes is present and addresses hidden diabetes and impaired glucose tolerance in patients with acute and stable coronary artery disease.
Journal ArticleDOI
Drug Trials for Older People
TL;DR: Suggested solutions include the abolition of age limits in new randomized controlled trials, and the routine measurement of frailty, with a new generation of randomizedcontrolled trials to establish whether treatments remain effective and safe in old age and increasing frailty.
Journal ArticleDOI
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A Bethel,Jennifer B. Green,Joanne E. Milton,Abdelouahid Tajar,Samuel S. Engel,Robert M. Califf,Rury R. Holman +6 more
TL;DR: The trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) as discussed by the authors was a randomized, double-blind, placebo-controlled trial exploring whether add-on insulin therapy to usual type 2 diabetes care affects time to first event in the composite endpoint of CV death, nonfatal myocardial infarction (MI), non-fatal stroke or unstable angina hospitalization.
Journal ArticleDOI
Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies.
TL;DR: Subgroup analysis showed that use of aspirin after diagnosis was associated with longer overall survival among patients with the variant PIK3CA gene but not for those with wild-type Pik3CA, and aspirin afterdiagnosis does reduce all-cause mortality for colorectal cancer patients.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.